Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TARGETSET

Financiado

Commercial feasibility of targeting the histone methyltransferase SETD8 in cance...

Commercial feasibility of targeting the histone methyltransferase SETD8 in cancer New chemical entities and biomarkers. Within our ERC CoG grant, RSHEALTH, our group has contributed to the to the preclinical development of chemical inhibitors of the ATR kinase as anticancer agents, that are now in clinical trials by several companies. During the co... ver más

31/12/2022

FUNDACION SECTOR P...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

FUNDACION SECTOR PUBLICO EST...

150.00K€ | Lider

ACCIONA CONSTRUCCION

13.86M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EpiPolyPharma Development of dual-targeting epigenetic modulators for poly... 173K€ Cerrado

SAF2017-85330-R DESARROLLO DE NUEVAS MOLECULAS, MODULADORES EPIGENETICOS, PA... 121K€ Cerrado

SAF2013-48397-R SINTESIS DE NUEVOS MODULADORES DE ENZIMAS EPIGENETICAS INSPI... 363K€ Cerrado

MYCinTOPshape Mechanism and targeting of topoisomerase regulatory interact... 2M€ Cerrado

SAF2010-17935 DISEÑO Y SINTESIS DE NUEVOS MODULADORES DE ENZIMAS EPIGENETI... 363K€ Cerrado

ONCODESTROYER Targeting cancer vulnerabilities in acute leukemia 3M€ Cerrado

Duración del proyecto: 22 meses Fecha Inicio: 2021-02-02
Fecha Fin: 2022-12-31

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 150K€

Descripción del proyecto Within our ERC CoG grant, RSHEALTH, our group has contributed to the to the preclinical development of chemical inhibitors of the ATR kinase as anticancer agents, that are now in clinical trials by several companies. During the course of our investigations, we also made important advances in developing inhibitors of SETD8, another interesting cancer-related target. SETD8 is a histone methyltransferase known to play important roles in DNA replication and repair. Evidence indicating that targeting SETD8 could be interesting for cancer therapy has been building up in recent years. For instance, SETD8 is overexpressed in a wide range of cancers, and recent works identified SETD8 as a specific vulnerability in High-Risk Neuroblastoma or MYC-driven Medulloblastomas. Unfortunately, all available SETD8 inhibitors have low potency and poor pharmacological properties, and none has progressed to the clinic. We here propose to capitalize in our strengths in academic drug development, and our experience in transferring our inhibitors to the industry, in order to facilitate the clinical development SETD8 inhibitors. Our proposal includes objectives that will help us improve the quality of our inhibitors, valorise them in preclinical cancer models and develop companion biomarkers that would be used for patient stratification. All of this would be integrated within a business plan that should facilitate a coherent development of this line of work oriented towards the clinical development of SETD8 inhibitors for the benefit of cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores